Chelsea Therapeutics International Ltd., of Charlotte, N.C., dosed its first patient in Study 401, a trial of Northera (droxidopa) for neurogenic orthostatic hypotension in patients with primary autonomic failure, dopamine beta hydroxylase deficiency, and non-diabetic autonomic neuropathy.